Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Chief Legal & Admin Officer | March 15, 2026 | March 17, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | EVP & General Counsel | May 15, 2025 | May 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date March 15, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,943 |
Reported balance
After 2026-03-15 transaction · row 1
1 source rowRow 1 · 2026-03-15 · Grant · Acquired 20,646 · Balance 107,943 F1: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.06 · Expires 2036-03-14 | Direct | 8,325 |
Reported balance
After 2026-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-15 · Grant · Acquired 8,325 · Balance 8,325 F2: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.06 · Expires 2036-03-14 | Direct | 22,820 |
Reported balance
After 2026-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-15 · Grant · Acquired 22,820 · Balance 22,820 F3: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
F2: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
F3: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
EXELIXIS, INC.
Report date May 15, 2025 · Filed May 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 693,396 |
Last balance in matching sequence
After 2025-05-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-05-15 · Tax withholding · Disposed 34,035 · Balance 718,396 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024. F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2025-05-15 · Sale · Disposed 25,000 · Balance 693,396 F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 999 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 999 F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024.
F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2020 Filed Sep 11, 2020 00:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 59,692 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · derivative · entry 5 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 59,692 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Common Stock, became fully exercisable on April 28, 2016. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 00:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 160,666 | $20.71 | $3,327,392.86 |
DisclosureSEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,026 F2 · kind: Represents a "net exercise" of outstanding stock options. The Reporting Person received 89,026 shares of Common Stock on the net exercise of stock options to purchase 249,692 shares of Common Stock. The Issuer withheld 160,666 shares of Common Stock underlying the stock options for payment of the exercise prices and tax withholdings using a stock price on September 8, 2020 of $20.71. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 00:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 190,000 | $6.21 | $1,179,900.00 |
DisclosureSEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 00:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 59,692 | $1.90 | $113,414.80 |
DisclosureSEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39,058 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 22:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 1,311 | $21.58 | $28,291.38 |
DisclosureSEC source: 0000939767-20-000125 · wf-form4_159925911942541.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,000 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 22:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 4,998 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000125 · wf-form4_159925911942541.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,311 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 4,998 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 39,058 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 13, 2020 Filed May 16, 2020 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-20-000083 · wf-form4_158958843032722.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Common Stock, became fully exercisable on April 28, 2016. Read SEC document |
| May 13, 2020 Filed May 16, 2020 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 13,875 | $26.53 | $368,103.75 |
DisclosureSEC source: 0000939767-20-000083 · wf-form4_158958843032722.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,313 F2 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 11,125 shares of Common Stock on the net exercise of a stock option to purchase 25,000 shares of Common Stock. The Issuer withheld 13,875 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on May 13, 2020 of $26.53. Read SEC document |
| May 13, 2020 Filed May 16, 2020 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $1.70 | $42,500.00 |
DisclosureSEC source: 0000939767-20-000083 · wf-form4_158958843032722.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 36,559 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 11, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 38,006 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · derivative · entry 10 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,692 Underlying: Common Stock · 38,006 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| May 11, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 38,006 | $27.09 | $1,029,582.54 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · nonDerivative · entry 6 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,188 F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.94 to $27.23. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| May 11, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 38,006 | $1.90 | $72,211.40 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · nonDerivative · entry 5 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · derivative · entry 9 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,698 Underlying: Common Stock · 25,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| May 08, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $26.04 | $651,000.00 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · nonDerivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,188 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| May 08, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $1.90 | $47,500.00 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · derivative · entry 8 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,698 Underlying: Common Stock · 30,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 30,000 | $25.61 | $768,300.00 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,188 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.60 to $25.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $1.90 | $57,000.00 |
DisclosureSEC source: 0000939767-20-000077 · wf-form4_158924379144708.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 36,559 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,618 shares of common stock acquired on April 30, 2020, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 00:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,360 | $17.67 | $41,701.20 |
DisclosureSEC source: 0000939767-19-000203 · wf-form4_157567805659945.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,570 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 4, 2019. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 00:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 8,996 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000203 · wf-form4_157567805659945.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,930 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 8,996 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that Exelixis, Inc. has achieved a net product revenue target over four consecutive fiscal quarters; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 4, 2019, the Committee convened to determine that the net product revenue target over four consecutive fiscal quarters had been achieved during the three months ended September 27, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2021, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 36,559 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 02:42 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,131 | $16.51 | $35,182.81 |
DisclosureSEC source: 0000939767-19-000197 · wf-form4_157387212368522.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,934 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 02:42 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 6,557 | $16.51 | $108,256.07 |
DisclosureSEC source: 0000939767-19-000197 · wf-form4_157387212368522.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,065 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 32,061 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,292 shares of common stock acquired on October 31, 2019, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| September 12, 2019 Filed Sep 14, 2019 00:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 1,487 | $19.26 | $28,639.62 |
DisclosureSEC source: 0000939767-19-000173 · wf-form4_156842214746790.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,330 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 12, 2019. Read SEC document |
| September 12, 2019 Filed Sep 14, 2019 00:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 5,997 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000173 · wf-form4_156842214746790.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,817 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 5,997 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Compensation Committee's certification that Exelixis, Inc. has achieved a quarterly net product revenue target; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On September 12, 2019, the Committee convened to determine that the quarterly net product revenue target had been achieved during the three months ended June 28, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2020, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 48,623 shares of Exelixis, Inc. common stock that will be issued to the reporting person upon vesting of restricted stock units. Read SEC document |
| August 16, 2019 Filed Aug 21, 2019 00:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-19-000165 · wf-form4_156634797668675.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 75,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| August 16, 2019 Filed Aug 21, 2019 00:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 75,000 | $21.10 | $1,582,500.00 |
DisclosureSEC source: 0000939767-19-000165 · wf-form4_156634797668675.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,820 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.20. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| August 16, 2019 Filed Aug 21, 2019 00:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 75,000 | $1.70 | $127,500.00 |
DisclosureSEC source: 0000939767-19-000165 · wf-form4_156634797668675.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 45,624 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:01 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-19-000080 · wf-form4_155433604757836.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 20,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:01 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 20,000 | $24.03 | $480,600.00 |
DisclosureSEC source: 0000939767-19-000080 · wf-form4_155433604757836.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,820 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.15. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:01 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 20,000 | $1.70 | $34,000.00 |
DisclosureSEC source: 0000939767-19-000080 · wf-form4_155433604757836.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 45,624 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 30, 2018 Filed Dec 1, 2018 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 1,943 | $19.91 | $38,685.13 |
DisclosureSEC source: 0000939767-18-000242 · wf-form4_154362610864788.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,820 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.91 to $19.92. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 29, 2018 Filed Dec 1, 2018 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 1,116 | $19.51 | $21,773.16 |
DisclosureSEC source: 0000939767-18-000242 · wf-form4_154362610864788.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,763 Read SEC document |
| November 28, 2018 Filed Dec 1, 2018 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 11,759 | $19.12 | $224,832.08 |
DisclosureSEC source: 0000939767-18-000242 · wf-form4_154362610864788.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,879 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.11 to $19.13. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 45,624 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 1,404 | $17.45 | $24,499.80 |
DisclosureSEC source: 0000939767-18-000230 · wf-form4_154241737191595.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,638 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 4,408 | $17.45 | $76,919.60 |
DisclosureSEC source: 0000939767-18-000230 · wf-form4_154241737191595.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,042 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 45,624 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 129,314 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-18-000200 · wf-form4_153679746370589.xml · derivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,314 Underlying: Common Stock · 129,314 shares Expires 2025-09-09 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| May 31, 2018 Filed Jun 2, 2018 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 65,000 | $20.71 | $1,346,150.00 |
DisclosureSEC source: 0000939767-18-000117 · wf-form4_152789763605681.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,450 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.56 to $20.84. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 62,187 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 04, 2018 Filed May 8, 2018 00:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 20,000 | $22.36 | $447,200.00 |
DisclosureSEC source: 0000939767-18-000076 · wf-form4_152573800975845.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,450 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.20 to $22.52. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 62,187 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 27, 2018 Filed May 1, 2018 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-18-000062 · wf-form4_152513420417985.xml · derivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 25,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| April 27, 2018 Filed May 1, 2018 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $1.70 | $42,500.00 |
DisclosureSEC source: 0000939767-18-000062 · wf-form4_152513420417985.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 62,187 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,008 shares of common stock acquired on April 30, 2018, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| December 21, 2017 Filed Jan 20, 2018 01:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-18-000005 · wf-form5_151641124605599.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,442 F1 · balance_after: Includes 62,187 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2017 Filed Nov 18, 2017 00:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,120 | $24.75 | $52,470.00 |
DisclosureSEC source: 0000939767-17-000192 · wf-form4_151096591636940.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,942 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. F2 · balance_after: Includes 62,187 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,116 shares of common stock acquired pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan on October 31, 2017. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-17-000169 · wf-form4_150724734336550.xml · derivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-10-02 F5 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000169 · wf-form4_150724734336550.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,946 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2018, and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully-vested. F3 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · derivative · entry 7 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,698 Underlying: Common Stock · 25,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $24.32 | $608,000.00 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · nonDerivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,946 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.20 to $24.40. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $1.90 | $47,500.00 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 2,302 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · derivative · entry 6 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,698 Underlying: Common Stock · 2,302 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 2,302 | $23.90 | $55,017.80 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,946 Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 2,302 | $1.90 | $4,373.80 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.